Digitala Vetenskapliga Arkivet

Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs
Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Pharm & Pharmaceut Sci, Dublin, Ireland..ORCID-id: 0000-0003-0730-1829
Mylan Global Resp Grp, Sandwich, Kent, England..ORCID-id: 0000-0001-6210-8461
Univ Poitiers, CHU Poitiers, UFR Med Pharm, Inserm,U1070, Poitiers, France..
GlaxoSmithKline Medicines Res Ctr, Refractory Resp Inflammat DPU, Stevenage, Herts, England..
Visa övriga samt affilieringar
2017 (Engelska)Ingår i: Journal of Pharmaceutical Sciences, ISSN 0022-3549, E-ISSN 1520-6017, Vol. 106, nr 9, s. 2234-2244Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

The School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin hosted the "1st Workshop on Drug Transporters in the Lungs" in September 2016 to discuss the impact of transporters on pulmonary drug disposition and their roles as drug targets in lung disease. The workshop brought together about 30 scientists from academia and pharmaceutical industry from Europe and Japan and addressed the primary questions: What do we know today, and what do we need to know tomorrow about transporters in the lung? The 3 themes of the workshop were: (1) techniques to study drug transporter expression and actions in the lungs; (2) drug transporter effects on pulmonary pharmacokinetics-case studies; and (3) transporters as drug targets in lung disease. Some of the conclusions of the workshop were: suitable experimental models that allow studies of transporter effects are available; data from these models convincingly show a contribution of both uptake and efflux transporters on pulmonary drug disposition; the effects of transporters on drug lung PK is now better conceptualized; some transporters are associated with lung diseases. However, more work is needed to establish which of the available models best translate to the clinical situation.

Ort, förlag, år, upplaga, sidor
2017. Vol. 106, nr 9, s. 2234-2244
Nyckelord [en]
absorption, computational ADME, efflux pumps, in vitro models, organic cation transporters, P-glycoprotein, peptide transporters, pulmonary delivery/absorption, ABC transporters, organic anion-transporting polypeptide transporters
Nationell ämneskategori
Farmaceutiska vetenskaper
Identifikatorer
URN: urn:nbn:se:uu:diva-344532DOI: 10.1016/j.xphs.2017.04.011ISI: 000417339900010PubMedID: 28416418OAI: oai:DiVA.org:uu-344532DiVA, id: diva2:1188419
Tillgänglig från: 2018-03-07 Skapad: 2018-03-07 Senast uppdaterad: 2018-03-07Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Sök vidare i DiVA

Av författaren/redaktören
Ehrhardt, CarstenBackman, PerFridén, Markus
Av organisationen
Institutionen för farmaceutisk biovetenskap
I samma tidskrift
Journal of Pharmaceutical Sciences
Farmaceutiska vetenskaper

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 104 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf